EASD Honorary Secretary Tina Vilsbøll guides through the episode with an overview and a summary. Michael Nauck assesses the possible place of GLP-1 receptor agonists in type 1 diabetes. Peter Rossing presents key results from the FLOW study, which specifically investigated the effects of semaglutide in high risk renal patients. Daniel Drucker outlines how to manage adverse effects and safety aspects of GLP-1 receptor agonists in alliance with those taking them.